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Abstract The use of antipsychotics is hindered by the
frequent occurrence of metabolic and cardiovascular side
effects, resulting in worsened quality of life and greater
mortality as a result of cardiovascular and cerebrovascular
disorders in schizophrenia patients than the comparable
general population. The various antipsychotics induce
extrapyramidal symptoms, impaired glucose and lipid
metabolism, weight gain, hypertension and arrhythmias,
with variable frequency. Second-generation antipsychotics
appear to have several advantages over first-generation
antipsychotics, including a claimed better action on cog-
nitive function and the negative symptoms of schizophre-
nia, and lower frequency of extrapyramidal side effects;
however, their use is associated with a greater frequency
of metabolic and cardiovascular disturbances. The mecha-
nisms of these important side effects are not well understood,
and generic approaches (psychoeducational programmes
and symptomatic therapies) have been proposed to limit
their severity. Extensive data from the literature indicate
that autonomic nervous system dysfunction—intrinsic to
schizophrenia and strongly exacerbated by antipsychotic
treatment—is the cause of the pervasive metabolic and
vascular dysfunctions associated with schizophrenia. In this
article, we marshal further literature data to argue that the
metabolic and cardiovascular side effects of antipsychotics
are primarily mediated by their ability to block peripheral
dopamine receptors, which physiologically modulate sympa-
thetic activity. We also propose that these effects might be
overcome by providing peripheral dopaminergic stimulation.
1 Introduction
Compared with first-generation antipsychotics (FGAs),
second-generation antipsychotics (SGAs) seem character-
ized by reduced risk of extrapyramidal motor side effects
but high frequency of adverse metabolic events [1]. Insulin
resistance, weight gain with abdominal obesity, impaired
glucose tolerance, diabetes mellitus, dyslipidaemia, essen-
tial hypertension—major diagnostic criteria for metabolic
syndrome[2]—all occur frequently in patients treated with
SGAs [1]. Metabolic syndrome is a major cardiovascular
risk factor in schizophrenia patients, and is associated
with greater mortality due to cardiovascular and cere-
brovascular diseases than the comparable general popu-
lation [3]. Furthermore, all antipsychotics (FGAs and
SGAs) can cause severe and sometimes fatal cardiac
arrhythmias [4].
Although the metabolic derangement and cardiovascular
disorders associated with antipsychotic use are well rec-
ognized, a comprehensive mechanism able to account for
all these effects has not been proposed, so it is time to
examine new pathogenetic mechanisms that might account
for them. We propose a new pathogenetic mechanism for
these effects supported by a MEDLINE search using the
search terms metabolic syndrome, insulin resistance, dia-
betes, dyslipidaemia, hyperglycemia, weight gain, sympa-
thetic, histamine, serotonin, dopamine, triglycerides,
cholesterol, hypertension, cardiovascular disorders and
sudden cardiac death, cross-referenced with the term
schizophrenia. We examined papers published in English
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between 1980 and 2012 and checked references in relevant
papers to identify additional studies.
2 Schizophrenia as an Independent Risk Factor
for Metabolic Syndrome
Impaired glucose metabolism was described in psychiatric
patients before antipsychotics were introduced in the 1950s
[5]. Although disputed by some authors [6, 7], drug-naı¨ve
and first-episode patients with schizophrenia seem to have
impaired fasting glucose tolerance, more insulin resistance
and higher levels of plasma glucose, insulin and cortisol
than healthy control subjects. [8] Moreover, antipsychotic-
naive and antipsychotic-free schizophrenia patients have
significantly greater visceral adiposity than age- and sex-
matched controls, despite similar subcutaneous adiposity
[9–11]. Intra-abdominal adiposity is much more strongly
linked to insulin resistance and type 2 diabetes than excess
subcutaneous fat [12].
These metabolic disturbances in patients with schizo-
phrenia have been attributed to sedentary lifestyle, poor
diet and smoking [1]. However, increased sympathetic-
adrenal activity [13], with high plasma levels of catechol-
amines and cortisol [14], has also been observed in
untreated schizophrenia patients. Increased sympathetic-
adrenal activity could be a consequence of psychosis-
related stress [15], but could also be an effect of nicotine,
as these patients are often heavy smokers. Nicotine acts on
nicotinic (cholinergic) receptors in sympathetic ganglia,
activating postganglionic neurons and stimulating the
secretion of catecholamines from their terminals [16].
Smoking is associated with insulin resistance [17],
dyslipidaemia [18] and an increased propensity for type 2
diabetes [19, 20] through a body mass index-independent
mechanism [21]. Contrary to what one might expect,
stopping smoking does not reduce these metabolic abnor-
malities but, by mechanisms not well understood, is often
accompanied by increased weight and a further increase in
the risk of diabetes [22, 23].
2.1 Metabolic and Cardiovascular Effects
of Sympathetic Overactivity
High circulating levels of noradrenaline (norepinephrine),
adrenaline (epinephrine) and cortisol oppose the anabolic
effects of insulin and can induce metabolic changes. Thus,
by activating a2-adrenoreceptors, noradrenaline and
adrenaline promote the transformation of liver and muscle
glycogen to free glucose, enhance glucagon secretion and
inhibit insulin release from the pancreatic islets [24],
inducing hyperglycaemia; they also act on b2-adrenore-
ceptors in muscle and adipose tissue to reduce glucose
uptake and utilization by these tissues, promoting insulin
resistance [25]. In addition, noradrenaline and adrenaline
stimulate adipose lipolysis, promoting the release of glyc-
erol, free fatty acids, leptin, adiponectin and proinflam-
matory cytokines into the circulation [26]. The latter three
substances are implicated in obesity [27] (see Sect. 3).
Increased fatty acid levels contribute to the development of
insulin resistance [27] and stimulate the assembly and
secretion of very low density and low-density lipoproteins
(LDLs) by the liver, so that plasma levels of triglycerides
and LDL-cholesterol increase, and high-density lipoprotein
(HDL)-cholesterol decreases [28].
Thus, sympathetic overactivity correlates with hyper-
cholesterolaemia and hypertriglyceridaemia. It is note-
worthy that serum cholesterol levels are significantly
reduced in animals treated with 6-hydroxydopamine, a
sympathetic nervous system toxin [29].
Cortisol also increases insulin resistance, further con-
tributing to high levels of circulating glucose and lipids;
and in the long term, cortisol promotes abdominal fat
accumulation and stimulates the intake of carbohydrates
and fat [30].
Finally, excessive sympathetic tone has a major effect
on the cardiovascular system: it is implicated in cardio-
vascular hypertrophy and vulnerability to arrhythmias, and
plays a pathogenetic role in essential hypertension by
raising cardiac output and heart rate, and increasing
peripheral resistance and renin production [31]. Cardiac
effects of adrenergic activity are mediated mainly by
b1-receptors, although b2- and a-adrenoceptors are also
involved. b-Adrenoceptor activation increases both normal
(sinoatrial node) and abnormal (Purkinje fibres) pacemaker
activity.
3 Worsening of Metabolic Syndrome by Antipsychotics
The metabolic syndrome that characterizes many untreated
patients diagnosed with schizophrenia can worsen after a
few months’ treatment with antipsychotics [1, 11, 32]. This
happens more frequently with SGAs than FGAs, and with
greater probability for some SGAs than others [32, 33].
The prevalence of metabolic syndrome increases with
duration of treatment [32].
SGAs are a heterogeneous class of drugs, each agent
having differing pharmacological properties and a unique
binding profile to multiple receptors, which determine
differences in efficacy and side effects [34].
Increased body weight is usually linked to insulin
resistance (major cause of metabolic syndrome) [35] and to
changes in plasma glucose and lipid levels, but obesity
cannot be the causative factor for most cases of diabe-
tes arising during antipsychotic treatment [36]. Dose-
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dependent insulin resistance occurs following acute clo-
zapine and olanzapine administration in rats [37], indicat-
ing an immediate effect of these agents on metabolic
variables. Some [38, 39], but not all [40], studies have
found that antipsychotics have a similar short-term effect in
humans. In particular, rapid onset of diabetes has been
documented after the initiation of antipsychotic therapy,
together with rapid disappearance of diabetes after dis-
continuation [41]—too rapid to be explained by changes in
body weight.
Clozapine and olanzapine use appears to be associated
with greatest risk of metabolic syndrome; iloperidone, que-
tiapine, risperidone, paliperidone, sertindole and zotepine
are associated with intermediate risk; while amisulpride,
aripiprazole, asenapine, lurasidone and ziprasidone are
associated with only a small increase in risk [11, 42]. One
study found that the increased risk of diabetes was identical
in users of olanzapine, quetiapine and risperidone [43]. No
antipsychotic is completely free of metabolic side effects
[44]; even those usually without such effects may cause them
in specific situations. Thus, although aripiprazole does not
increase body weight in adults, weight gain has been reported
in paediatric patients following aripiprazole administration
[45, 46]. Furthermore, long-term side effects tend to come to
light only after a drug has been on the market for some time
[47], and most data on the side effects of antipsychotics have
been obtained from trials on patients with many years of prior
drug exposure, and this could lead to the underestimation of
side effects in the more recently introduced antipsychotics
such as aripiprazole, asenapine, lurasidone and ziprasidone
[48]. Finally, metabolic alterations appear to be an intrinsic
effect of antipsychotics, since they appear when these drugs
are employed to treat diseases other than schizophrenia [49, 50].
4 Previously Proposed Mechanisms for Metabolic Side
Effects of Antipsychotics
Despite a large body of research, no specific neurotrans-
mitter or receptor has been identified as the main cause of
the metabolic derangement often induced by antipsychotics
[51]. Since antipsychotic-induced obesity seems to be
related more to increased calorie intake than reduced
thermogenesis [52], the antagonistic action of antipsy-
chotics on receptors involved in the control of satiety,
feeding and glucose metabolism, and their interactions with
orexigenic and anorexigenic peptides have been exten-
sively investigated [53]. Antipsychotic-induced weight
gain has been proposed as due to antagonistic effects at,
among the others, the histamine H1 [54, 55], serotonin
5-HT2C [56] and dopamine D2 [57] receptors; while the
diabetogenic effect has been correlated with binding
affinity to H1 [55], 5-HT2C and muscarinic acetylcholine
receptors [34]. In fact, antagonism at 5-HT2C receptors
increases insulin resistance and reduces glucose uptake by
skeletal muscle, increasing the risk of diabetes [55].
However, antipsychotics such as clozapine, olanzapine,
risperidone, sertindole and zotepine have different pro-
pensities for inducing metabolic effects, even though they
have similar and only moderate binding affinity for 5-HT2C
receptors; moreover ziprasidone, which has the most potent
binding [58], is apparently largely free of metabolic side
effects. It therefore appears difficult to reconcile the vari-
able ability of antipsychotics to induce metabolic changes
with their binding to the 5-HT2C receptor.
The receptor binding profiles involved in dyslipidaemia
have not yet been identified [34].
Turning to consider acetylcholine receptors, antagonism
at muscarinic M3 receptors on pancreatic b cells (as shown
by olanzapine and clozapine), with consequent suppression
of cholinergic-stimulated insulin secretion, has also been
suggested as a cause of the metabolic effects of some SGAs
[45, 59]. However, when selective M3 antagonists are used
to treat patients with urinary incontinence they have not
been associated with increased risk of diabetes. Further-
more, insulin and glucose clearance responses to the oral
glucose tolerance test in vagotomized humans do not differ
substantially from those of healthy controls [60]. It is likely
therefore that M3 antagonism is only a precipitating factor
for diabetes in patients treated with antipsychotics.
Leptin, ghrelin and adiponectin—peptide hormones
involved in the regulation of appetite and body weight—
might be involved in the metabolic syndrome induced by
antipsychotics [61]. Leptin is a cytokine-like molecule
produced by subcutaneous adipocytes and actively trans-
ported into the hypothalamus where it acts to limit food
intake. However, most patients on antipsychotics have
increased, not reduced, blood levels of leptin, suggesting
that leptin increase is a consequence (not a cause) of
increased body weight, or that leptin resistance has
developed [61]. Ghrelin is a hunger-inducing hormone
produced in the stomach that regulates feeding behaviour
through central activity. Plasma levels of ghrelin have been
reported increased, unchanged and reduced in various
studies on schizophrenia patients treated with antipsy-
chotics [61]. Adiponectin is secreted by adipose tissue and
circulating levels correlate inversely with body weight and
insulin resistance. As with studies on ghrelin, studies on
adiponectin levels in antipsychotic-induced weight gain
have produced conflicting results [61]. For more data on
these peptides and antipsychotic-induced metabolic side
effects see the following review articles [45, 48, 61, 62].
The appearance of metabolic side effects in some but
not all patients treated with a given antipsychotic suggests
the involvement of genetic factors. Gene polymorphisms
may occur at the level of drug transporters, metabolizing
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enzymes or the protein targets (receptors) of the drug.
Antipsychotic-induced weight gain is associated with a
polymorphism of the promoter region of the 5-HT2C
receptor gene and a functional polymorphism of the leptin
gene [63]. Associations of increased risk of metabolic
syndrome with polymorphisms of the MTHFR gene [64]
and the D2 receptor gene [65] have been suggested in
patients receiving SGAs.
From the above survey, it is evident that a convincing
account of the mechanisms responsible for the frequent and
severe metabolic side effects of SGAs is not available. We
suggest that the main mechanism for these effects is
deranged autonomic function due first to the ability of these
agents to block peripheral dopamine receptors, which
increases sympathetic activity (see Sect. 5 for the proposed
mechanism); and secondly to the ability of some of these
agents to also block peripheral muscarinic receptors, which
reduces vagal parasympathetic activity.
5 The Missing Piece of the Puzzle: The Peripheral
Dopaminergic System
Outside the CNS, dopamine has been traditionally viewed as
an inactive precursor of noradrenaline and adrenaline.
However, dopamine receptors are widespread peripherally,
being present for example in heart, kidneys, adrenal glands,
liver, endocrine pancreas and resistance vessels such as
renal, coronary, pulmonary, mesenteric and cerebral arteries
[66]. D1 and D5 (D1-like), and D2, D3 and D4 (D2-like)
receptor subtypes have not been extensively investigated in
peripheral organs, hence for convenience we apply the D1/D2
classification of Kebabian and Calne [67].
Stimulation of D1 receptors, located postsynaptically in
renal, mesenteric and splenic arteries, causes direct vasodi-
latation; and by reducing vascular resistance reduces blood
pressure [68]. D2 receptors are located presynaptically on
postganglionic sympathetic neurons and on adrenal chro-
maffin cells: their activation inhibits noradrenaline release
from nerve endings, and adrenaline secretion from the
adrenal medulla [66, 69], resulting in indirect vasodilatation,
reduced cardiac contractility and anabolic effects through
inhibition of sympathetic tone. These data suggest that the
peripheral dopaminergic system is an important modulator
of the endocrine and cardiovascular systems [68, 69]. In fact,
during intense sympathetic stimulation, endogenous dopa-
mine (in addition to noradrenaline and adrenaline) is secreted
and serves to modulate sympathetic discharge [70]. It is not
surprising, therefore, that full D2 receptor agonists have
proven effective in reducing blood pressure and plasma
glucose and lipids, thereby ameliorating some aspects of
metabolic syndrome [68, 71, 72]. Moreover, partial dopa-
mine agonists employed in the treatment of psychosis (e.g.
aripiprazole) do not seem to cause metabolic syndrome [42],
probably thanks to their stimulating action on extracerebral
presynaptic D2 receptors.
5.1 Metabolic Effects of Peripheral Dopamine D2
Receptor Blockade
Although the various antipsychotics have differing effects,
attributable to differences in their binding to dopamine,
serotonin, histamine, glutamate, muscarinic and a-adren-
ergic receptors, all effective antipsychotics block D2
receptors—including peripheral D2 receptors—with vary-
ing potency and dose-dependent effects [34]. Even anti-
psychotics such as clozapine, generally believed to have
very low affinity for D2 receptors, probably occupy more
than 70 % of these receptors, although more loosely than
FGAs [73]. When antipsychotics bind to the D2 receptor
they prevent activation by endogenous dopamine, so the
modulating effect of dopamine on the sympathetic-adrenal
system is inhibited. This effect is illustrated by the
peripheral D2 antagonist domperidone: administration of
this agent, which does not cross the blood-brain barrier
except in rare cases of blood-brain barrier immaturity or
disruption [74], significantly increases the release of both
adrenal noradrenaline and adrenaline [75], and reverses the
antihypertensive effect of dopaminergic drugs [76].
Thus, we arrive at the central hypothesis of the present
paper: chronic D2 receptor blockade by antipsychotics
abolishes peripheral dopaminergic modulation, resulting in
chronically increased sympathetic tone, in turn leading to
impaired control of glucose and lipid metabolism, chronic
increase in blood pressure, and increased propensity for
cardiac arrhythmias (Fig. 1).
Two findings provide strong circumstantial support for
this sequence of events: First, catecholamine levels are
increased in the plasma and cerebrospinal fluid of schizo-
phrenia patients on long-term antipsychotic treatment—
and are reduced after these drugs are withdrawn [77, 78].
Second, the hyperglycaemic response to acute administration
of high doses of antipsychotics in the mouse is completely
blocked by pretreatment with yohimbine (an a2-adrenoceptor
antagonist), suggesting that the hyperglycaemic effect is due,
at least in experimental animals, to increased sympathetic
nervous system activity [79].
5.2 Cardiovascular Effects of Peripheral D2 Receptor
Blockade
The hypertension sometimes present in patients being
treated with antipsychotics [80] can be controlled by b-
blockers [81], suggesting that adrenergic hyperactivity is
involved. Increased sympathetic tone is known to play a
major role in the genesis of essential hypertension [31]. In
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this context, it is noteworthy that catecholamine release is
increased in isolated cat adrenal glands perfused with an-
tipsychotics, and reduced by apomorphine (dopaminergic
agonist), confirming the existence, in adrenal glands, of a
dopaminergic system that inhibits catecholamine release
and can be inactivated by the administration of antipsy-
chotics, in turn suggesting the adrenal medulla as a pos-
sible site of action for the hypertensive response evoked by
antipsychotics [82].
Use of both FGAs and SGAs is also associated with a
dose-related increased risk of sudden death due to cardiac
arrhythmia [4]. Antipsychotics prolong the electrocar-
diogram QT interval and this has been identified as an
important trigger for torsades de pointes, a transient and
unpredictable form of polymorphic ventricular tachycar-
dia [83]. The magnitude of the sudden death risk varies
between studies—often just case reports—but seems to be
at least as high for SGAs as for FGAs [83]. Strikingly, it
took around 50 years of use before the US FDA issued its
warning (September 2007) regarding the association of
haloperidol with QT prolongation and arrhythmias. We
suggest that cardiac D2 receptor blockade by antipsy-
chotics is responsible for the increased sudden deaths due
to cardiac arrhythmias in FGA and SGA users. In fact,
increased sudden death for this cause has also been
reported after intravenous administration of the selective
peripheral D2 antagonist domperidone [84]. Cardiac D2
receptor blockade by antipsychotics would increase this
risk by inhibiting the modulator effect that endogenous
dopamine exerts on sympathetic activity. The resulting
enhanced stimulation of adrenergic receptors reduces
refractory period duration, and may lead to the initiation of
torsades de pointes [85].
5.3 Additional Mechanisms
If D2 receptor blockade by antipsychotics is the main
reason why metabolic derangements are common in users
of these drugs, then haloperidol and ziprasidone, the most
potent D2 blockers [34], should be most strongly associated
with these derangements. This is not the case however
since, as noted above, clozapine and olanzapine, followed
by quetiapine, appear mainly responsible for these effects
[42]. This conflict can be explained by considering that D2
blockade increases the availability of noradrenaline and
adrenaline (sympathetic activity) but these catecholamines
can exert their effects only if the following occurs:
(a) Adrenergic receptors are free. We know, for example,
that antipsychotics block the a1- and a2-adrenoceptors
with variable affinity, so the increased availability of
an adrenergic neurotransmitter does not produce any
metabolic or cardiovascular effect if receptor occu-
pancy is already high and the proportion of receptors
remaining active is low. Net adrenergic activity can even
be reduced if receptor occupancy by antipsychotics is
high. In fact, orthostatic hypotension may occur—
instead of hypertension—as a side effect of antipsy-
chotic use, due to a1-adrenoceptor antagonism [86].
(b) Parasympathetic activity does not counteract their
actions. Parasympathetic activity opposes sympa-
thetic effects on the pancreatic islets [24] and the
Fig. 1 Schematic outline of proposed effects of antipsychotics on
sympathetic and parasympathetic outflow. Antipsychotics block
peripheral dopamine D2, a-adrenergic, and cholinergic M3 receptors.
Physiologically, D2 receptors modulate the release of catecholamines
from sympathetic terminals and the adrenal glands. D2 receptor
blockade causes increased release of catecholamines. If the a-adrenergic
receptors are not completely occupied by an antipsychotic, sympathetic
activity is increased, and would normally be balanced by increased
parasympathetic tone. If, however, M3 receptors are also blocked by the
antipsychotic, sympathetic activity is no longer countered by parasym-
pathetic activity so the former exerts its well known clinical effects
leading to metabolic syndrome and arrhythmia
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cardiovascular system [87] by acting on cholinergic
M3 receptors. If these receptors are inhibited by
antipsychotics, the increased sympathetic activity is
no longer counterbalanced by parasympathetic activ-
ity and the net result is sympathetic overactivity. For
this reason, clozapine, olanzapine and quetiapine
(moderate binding at D2 but potent binding at M3
receptors) are strong inducers of metabolic side
effects, while haloperidol and ziprasidone—potent
binding at D2 but weak at M3 receptors—are much
less so [32, 42].
Antipsychotics also bind to a range of non-dopaminergic
targets, such as serotonin and histamine receptors, which
also play a role in weight gain and obesity [34], so the
ability of each antipsychotic to induce metabolic
derangements would be a result of its actions on all the
receptor systems involved in the maintenance of metabolic
homeostasis.
6 Findings in Parkinson’s Disease
Our hypothesis that D2 receptor blockade by antipsychotics
is responsible for metabolic syndrome, and ultimately con-
tributes to increased mortality in schizophrenia, is reinforced
by observations in Parkinson’s disease (PD), an illness in
which sympathetic degeneration and dopaminergic treat-
ment produce effects that are opposite to those found in
schizophrenia. One neuropathological hallmark of PD is
generalized sympathetic denervation, which is known to be
present even in patients without clinically evident autonomic
failure [88]. Reduced sympathetic activity accounts for the
reduced frequencies of hypertension, type 2 diabetes and
dyslipidaemia in untreated PD patients [89].
The main aim of pharmacological treatment in PD is
to stimulate D2 receptors, principally in the striatum.
Levodopa is still the most effective drug in this respect.
However, the quantities of levodopa-derived dopamine
present in the periphery (notwithstanding use of a peripheral
decarboxylase inhibitor) are sufficient to further reduce
sympathetic activity—via actions on peripheral D2 recep-
tors—further contributing to lowered frequencies of dia-
betes, hypertension and dyslipidaemia in PD patients
taking levodopa [90].
7 Overcoming the Metabolic and Cardiovascular Side
Effects of Antipsychotics
The arguments presented above make a strong case that the
metabolic and cardiovascular side effects of antipsychotics
hinge on their action on peripheral (extracerebral) dopa-
minergic, cholinergic and adrenergic receptors (although a
central component cannot be ruled out). The inhibitory
action of these antipsychotics on D2 receptors plays a
major role in this mechanism. It is therefore conceivable
that by displacing the antipsychotic from peripheral D2
receptors by means of a dopaminergic drug, the balance
between sympathetic and parasympathetic activity may be
restored, at least in part.
The administration of dopamine agonists to patients
with psychotic disorders may raise concerns, as the stim-
ulation of cerebral D2 receptors can exacerbate psychotic
symptoms. However, if the dopaminergic medication is
unable to cross the blood-brain barrier this risk is very low.
The dopaminergic drug that has these features is levo-
dopa. Levodopa itself is inactive, but is decarboxylated in
the body to active dopamine. However, over 90 % of
administered levodopa is decarboxylated outside the CNS,
and this dopamine does not cross the blood–brain barrier.
To overcome this problem when levodopa is administered
to parkinsonian patients, it is combined with a peripheral
dopa-decarboxylase inhibitor (carbidopa or benserazide) so
that more levodopa passes into the brain to increase the
amount of dopamine available there. By contrast, when
levodopa is used in the absence of a peripheral decarbox-
ylase inhibitor, its central action is minimized in favour of
its peripheral action. This property of levodopa is unique,
and its use with or without a peripheral decarboxylase
inhibitor allows differential targeting of dopamine to the
CNS and the periphery. SGAs such as clozapine, olanza-
pine and quetiapine bind the D2 receptor more weakly, and
have a higher dissociation constant, than dopamine [91]. It
is therefore theoretically possible to displace these anti-
psychotics from peripheral D2 receptors using relatively
low doses of levodopa, so that the probability of exacer-
bating psychotic symptoms would be low.
In fact, it is possible that very low levels of central
levodopa-derived dopamine might mimic the therapeutic
effects of partial dopamine agonists thought to act by
stimulating presynaptic D2 receptors. In vitro experiments
have shown that it is possible to produce a partial agonistic
effect by combining a full direct receptor agonist with a
full antagonist [92]. Slightly elevated central dopamine
levels might also promote quick dissociation of antipsy-
chotics from D2 receptors [91], improving their pharma-
cological profile.
In a review of 30 studies involving more than 700 patients,
Jaskiw and Popli reported that administration of high doses
of levodopa to patients with schizophrenia caused clinical
worsening (measured with various psychiatric rating scales)
in 20 % of cases when not associated with antipsychotics,
but a significant clinical improvement occurred in 50 % of
cases when antipsychotics were also administered. The
authors concluded that add-on levodopa may be beneficial in
patients already on antipsychotics [93]. It is noteworthy that
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the beneficial effects of levodopa prevailed over its negative
effects even though high doses of levodopa, associated with a
peripheral decarboxylase inhibitor, were given. It is note-
worthy, also, that levodopa has proved capable of attenuating
peripheral sympathetic activity in experimental animals
[94], and has been successfully used (without a decarbox-
ylase inhibitor) to treat congestive heart failure [95].
Levodopa has been widely used (and studied) for the
treatment of PD for over 50 years. It may cause nausea
when first given due to stimulation of dopaminergic
receptors in the area postrema, but this effect usually dis-
appears after a week or two. It is unlikely that this effect
will occur when combined with antipsychotic use, first,
because of the low doses proposed and, secondly, because
antipsychotics have an antagonistic effect on the dopami-
nergic receptors of the area postrema. The long-term side
effects of levodopa treatment in PD (‘on-off’, psychiatric
disturbances) are closely associated with progression of the
disease itself [96], and it has been shown that chronic
levodopa is not toxic for dopaminergic neurons [97].
8 Conclusions
Many cerebral and peripheral factors are involved in the
metabolic and cardiovascular side effects of antipsychotics.
We propose a new unifying pathogenetic hypothesis for
these effects in which autonomic nervous system dysfunc-
tion—triggered by the disease and exacerbated by antipsy-
chotic treatment—is at the root of the pervasive metabolic
and cardiovascular disorders that characterize patients with
schizophrenia. Our suggestion that levodopa may prevent
these side effects is both attractive and easily testable.
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